focus -WSS

focus

author：comprehensive 2025-10-06 14:01:44 - browse：637

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Test for long Covid? Researchers find new clue in blood samples

WSS

Eli Lilly, Pfizer, and others want in on the online prescription market

With psoriasis trial ahead, Alumis raises $259 million

What it’s like to watch children die of measles

Test for long Covid? Researchers find new clue in blood samples

Readout Newsletter: Merck, J&J, and long Covid

How to bring more disabled researchers into academia

focus

focus

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

NEJM study link tiny plastics in blood vessels to heart problems

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Just how do doctors, lawmakers, and the public define abortion?

State Dept. review finds Biden bears some blame for Afghanistan failures

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

After affirmative action ruling, medical educators look to 'holistic review'

NIH director takes cautious approach to Biden drug pricing priority

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

leisure time

What it’s like to watch children die of measles

Sen. Paul opposes bill to ban Chinese biotechs

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

UnitedHealth quietly bought dozens of outpatient centers

NIH director takes cautious approach to Biden drug pricing priority

Air quality improving but still lags in Black, Hispanic communities

Wikipedia

leisure time

explore

hotspot